Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Wang, DanZhong, Li
Li, Mengxin
Li, Jia
Tran, Karen
Ren, Lingzhi
He, Ran
Xie, Jun
Moser, Richard P.
Fraser, Cara
Kuchel, Tim
Sena-Esteves, Miguel
Flotte, Terence R.
Aronin, Neil
Gao, Guangping
UMass Chan Affiliations
Department of MedicineDepartment of Pediatrics
Department of Neurosurgery
Viral Vector Core
Department of Microbiology and Physiological Systems
Li Weibo Institute for Rare Diseases Research
Horae Gene Therapy Center
Document Type
Journal ArticlePublication Date
2018-10-04Keywords
CNS gene transferadeno-associated virus
gene therapy
large animals
neutralizing antibody
Genetics and Genomics
Immunoprophylaxis and Therapy
Molecular Biology
Therapeutics
Metadata
Show full item recordAbstract
Pre-existing neutralizing antibody (NAb) against adeno-associated virus (AAV) commonly found in primates is a major host barrier that can severely compromise in vivo gene transfer by AAV vectors. To achieve proof-of-concept success in clinical development of recombinant AAV (rAAV)-based in vivo gene therapy, it is crucial to consider the potential interference of NAb and to enroll serologically compatible study subjects. In this study, we report a large AAV NAb dataset comprising multiple large animal species and AAV serotypes and compare two NAb assays based on in vitro or in vivo transduction inhibition, respectively. Together with previously published AAV seroepidemiology studies, these data can serve as a reference for selecting suitable serotypes, study subjects of large animal species, and potentially human patients for rAAV treatment. In addition, we modeled the intrathalamus rAAV9 delivery in the presence of circulating anti-AAV9 NAb generated by either pre-immunization or passive transfer of NAb-positive large animal serum to mice. The data showed that circulating NAb may not be the sole determinant to inhibit braintransduction. Other aspects of pre-existing AAV immunity following natural infection or rAAV administration may be further studied to establish a more accurate inclusion criterion for clinical studies employing intraparenchymal rAAV9 injections.Source
Mol Ther Methods Clin Dev. 2018 Oct 4;11:65-72. doi: 10.1016/j.omtm.2018.09.003. eCollection 2018 Dec 14. Link to article on publisher's site
DOI
10.1016/j.omtm.2018.09.003Permanent Link to this Item
http://hdl.handle.net/20.500.14038/40785PubMed ID
30397628Related Resources
Rights
Copyright © 2018 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Distribution License
http://creativecommons.org/licenses/by-nc-nd/4.0/ae974a485f413a2113503eed53cd6c53
10.1016/j.omtm.2018.09.003
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2018 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).